Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly begins Alzheimer’s treatment trial

Eli Lilly begins Alzheimer’s treatment trial

2nd April 2008

The phase III clinical trial of a gamma secretase inhibitor for the treatment of Alzheimer’s disease has begun, Eli Lilly announced this week.

The pharmaceutical company said the study of LY450139, intended for use in patients suffering from mild to moderate forms of the condition, will involve a randomised double-blind placebo-controlled structure.

Named Identity, the trial will be conducted using 1,500 human subjects over a period of 21 months to discover whether the treatment can inhibit gamma secretase.

It is thought that this enzyme creates amyloid beta, a sticky protein which, when clumped together, destroys brain cells.

Eli Lilly said that current options for Alzheimer’s sufferers do not include any “documented effect” on amyloid beta, so the success of the trial would go some way to solving an unmet medical need.

“We are proud to announce the start of the Identity clinical trial and hold hope that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease,” commented Dr Eric Siemers, who is medical director of Alzheimer’s disease research for the group.

In related news, the BBC last week reported new research from the journal Neurology which claimed to find a link between larger waist sizes and risk of Alzheimer’s disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.